249 related articles for article (PubMed ID: 36139624)
1. Molecular Characterizations of Gynecologic Carcinosarcomas: A Focus on the Immune Microenvironment.
Nakad Borrego S; Lengyel E; Kurnit KC
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139624
[TBL] [Abstract][Full Text] [Related]
2. Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma.
Berton-Rigaud D; Devouassoux-Shisheboran M; Ledermann JA; Leitao MM; Powell MA; Poveda A; Beale P; Glasspool RM; Creutzberg CL; Harter P; Kim JW; Reed NS; Ray-Coquard I
Int J Gynecol Cancer; 2014 Nov; 24(9 Suppl 3):S55-60. PubMed ID: 25341582
[TBL] [Abstract][Full Text] [Related]
3. Carcinosarcomas and Related Cancers: Tumors Caught in the Act of Epithelial-Mesenchymal Transition.
Pang A; Carbini M; Moreira AL; Maki RG
J Clin Oncol; 2018 Jan; 36(2):210-216. PubMed ID: 29220296
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 Expression in Carcinosarcomas of the Gynecologic Tract: A Potentially Actionable Biomarker.
Pinto A; Mackrides N; Nadji M
Appl Immunohistochem Mol Morphol; 2018 Jul; 26(6):393-397. PubMed ID: 27801734
[TBL] [Abstract][Full Text] [Related]
5. Trends in Gynecologic Carcinosarcoma Based on Analysis of the Surveillance Epidemiology End Result (SEER) Database.
Lee JW; Ouh YT; Chang HK; Min KJ; Lee S; Hong JH; Song JY; Lee JK; Lee NW
J Clin Med; 2023 Feb; 12(3):. PubMed ID: 36769835
[TBL] [Abstract][Full Text] [Related]
6. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer.
Amant F; Cadron I; Fuso L; Berteloot P; de Jonge E; Jacomen G; Van Robaeys J; Neven P; Moerman P; Vergote I
Gynecol Oncol; 2005 Aug; 98(2):274-80. PubMed ID: 15972232
[TBL] [Abstract][Full Text] [Related]
7. Integrated Molecular Characterization of Uterine Carcinosarcoma.
Cherniack AD; Shen H; Walter V; Stewart C; Murray BA; Bowlby R; Hu X; Ling S; Soslow RA; Broaddus RR; Zuna RE; Robertson G; Laird PW; Kucherlapati R; Mills GB; ; Weinstein JN; Zhang J; Akbani R; Levine DA
Cancer Cell; 2017 Mar; 31(3):411-423. PubMed ID: 28292439
[TBL] [Abstract][Full Text] [Related]
8. Ovarian and uterine carcinosarcomas: a comparative analysis of prognostic variables and survival outcomes.
Garg G; Shah JP; Kumar S; Bryant CS; Munkarah A; Morris RT
Int J Gynecol Cancer; 2010 Jul; 20(5):888-94. PubMed ID: 20606539
[TBL] [Abstract][Full Text] [Related]
9. The case for HER2/neu as a therapeutic target for gynecologic malignancies.
Goyne HE; Cannon MJ
Immunotherapy; 2012 Aug; 4(8):781-4. PubMed ID: 22947006
[TBL] [Abstract][Full Text] [Related]
10. Molecular events in endometrial carcinosarcomas and the role of high mobility group AT-hook 2 in endometrial carcinogenesis.
Romero-Pérez L; Castilla MÁ; López-García MÁ; Díaz-Martín J; Biscuola M; Ramiro-Fuentes S; Oliva E; Matias-Guiu X; Prat J; Cano A; Moreno-Bueno G; Palacios J
Hum Pathol; 2013 Feb; 44(2):244-54. PubMed ID: 22974476
[TBL] [Abstract][Full Text] [Related]
11. Mismatch Repair Deficiency in Uterine Carcinosarcoma: A Multi-institution Retrospective Review.
Jenkins TM; Hanley KZ; Schwartz LE; Cantrell LA; Stoler MH; Mills AM
Am J Surg Pathol; 2020 Jun; 44(6):782-792. PubMed ID: 31934920
[TBL] [Abstract][Full Text] [Related]
12. HER2/neu as a potential target for immunotherapy in gynecologic carcinosarcomas.
Guzzo F; Bellone S; Buza N; Hui P; Carrara L; Varughese J; Cocco E; Betti M; Todeschini P; Gasparrini S; Schwartz PE; Rutherford TJ; Angioli R; Pecorelli S; Santin AD
Int J Gynecol Pathol; 2012 May; 31(3):211-21. PubMed ID: 22498937
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the relationship between adenosarcoma and carcinosarcoma and a hypothesis of the histogenesis of uterine sarcomas.
Seidman JD; Chauhan S
Int J Gynecol Pathol; 2003 Jan; 22(1):75-82. PubMed ID: 12496702
[TBL] [Abstract][Full Text] [Related]
14. Uterine Carcinosarcomas: Clinical, Histopathologic and Immunohistochemical Characteristics.
Chen X; Arend R; Hamele-Bena D; Tergas AI; Hawver M; Tong GX; Wright TC; Wright JD
Int J Gynecol Pathol; 2017 Sep; 36(5):412-419. PubMed ID: 28700424
[TBL] [Abstract][Full Text] [Related]
15. The High Mobility Group A1 (HMGA1) gene is highly overexpressed in human uterine serous carcinomas and carcinosarcomas and drives Matrix Metalloproteinase-2 (MMP-2) in a subset of tumors.
Hillion J; Roy S; Heydarian M; Cope L; Xian L; Koo M; Luo LZ; Kellyn K; Ronnett BM; Huso T; Armstrong D; Reddy K; Huso DL; Resar LMS
Gynecol Oncol; 2016 Jun; 141(3):580-587. PubMed ID: 27001612
[TBL] [Abstract][Full Text] [Related]
16. Genomic aberrations in carcinomas of the uterine corpus.
Micci F; Teixeira MR; Haugom L; Kristensen G; Abeler VM; Heim S
Genes Chromosomes Cancer; 2004 Jul; 40(3):229-46. PubMed ID: 15139002
[TBL] [Abstract][Full Text] [Related]
17. Uterine carcinosarcoma and high-risk endometrial carcinomas: a clinicopathological comparison.
Zhang C; Hu W; Jia N; Li Q; Hua K; Tao X; Wang L; Feng W
Int J Gynecol Cancer; 2015 May; 25(4):629-36. PubMed ID: 25633654
[TBL] [Abstract][Full Text] [Related]
18. Fbxw7 is a driver of uterine carcinosarcoma by promoting epithelial-mesenchymal transition.
Cuevas IC; Sahoo SS; Kumar A; Zhang H; Westcott J; Aguilar M; Cortez JD; Sullivan SA; Xing C; Hayes DN; Brekken RA; Bae-Jump VL; Castrillon DH
Proc Natl Acad Sci U S A; 2019 Dec; 116(51):25880-25890. PubMed ID: 31772025
[TBL] [Abstract][Full Text] [Related]
19. Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin.
Growdon WB; Roussel BN; Scialabba VL; Foster R; Dias-Santagata D; Iafrate AJ; Ellisen LW; Tambouret RH; Rueda BR; Borger DR
Gynecol Oncol; 2011 Apr; 121(1):212-7. PubMed ID: 21168197
[TBL] [Abstract][Full Text] [Related]
20. Carcinosarcoma of the uterus-a single institution retrospective analysis of the management and outcome and a brief review of literature.
Anupama R; Kuriakose S; Vijaykumar DK; Pavithran K; Jojo A; Indu RN; Sheejamol VS
Indian J Surg Oncol; 2013 Sep; 4(3):222-8. PubMed ID: 24426726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
